Clinical Trial Update: A Study Of PF-03463275 As Add-On Therapy In Outpatients With Persistent Negative Symptoms Of Schizophrenia [Phase 2]

View source ↗

Summary

A Phase 2 add-on trial of PF-03463275 in outpatients with persistent negative symptoms of schizophrenia was terminated. No efficacy results are provided in the …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Schizophrenia

Drugs mentioned

• PF-03463275 (PF-03463275)

Snippet

Sponsor: Pfizer | Conditions: Schizophrenia | Phase 2 | Status: TERMINATED